APTEVO THERAPEUTICS INC.

Ajouter à une liste

Communiqués Aptevo Therapeutics Inc. Nasdaq

Actions

APVO

US03835L5049

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 31/08/2026			Varia. 5j.	Varia. 1 janv.
2,440 ^USD	+3,17%		+1,24%	-74,13%

14/08	Aptevo Therapeutics Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
27/07	Aptevo Therapeutics Inc. annonce une nouvelle stratégie dans les tumeurs solides et le dépôt d'une demande de brevet pour sa structure propriétaire à double ciblage Nectin-4 x PD-L1	CI

Communiqués

17/08	Aptevo Therapeutics Announces Closing of Existing Warrants Exercise and PIPE for $4.5 Million Gross Proceeds	AQ
14/08	Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results	AQ
13/08	Aptevo Therapeutics : Announces Closing of Existing Warrants Exercise and PIPE for $4.5 Million Gross Proceeds	PU
12/08	Aptevo Therapeutics Announces Exercise of Existing Warrants and PIPE for $4.5 Million Gross Proceeds	AQ
27/07	Aptevo Strengthens Solid Tumor Strategy with Patent Filing for Nectin-4 x PD-L1 Dual Targeting Backbone	AQ
30/06	Aptevo Secures $1.5 Million Non-Dilutive Research Grant From the Andy Hill Care Fund to Advance APVO451, a Nectin-4-Targeted Trispecific Immunotherapy for Solid Tumors	AQ
09/06	As Big Pharma Bets On Radiopharmaceuticals, Aptevo And Niowave Join Forces To Advance Novel Targeted Cancer Therapeutics In The $17B+ Oncology Category	EQ
28/05	Aptevo Therapeutics Appoints Mary J. Janatpour, Ph.D., as Senior Vice President & Chief Scientific Officer	AQ
27/05	Aptevo and Niowave Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Development, Includes Strategic Equity Investment by Niowave at Closing	AQ
13/05	Aptevo Therapeutics Provides a 1Q26 Business Update; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection	AQ
06/05	Aptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection	AQ
27/03	Aptevo's Mipletamig Shows 86% Clinical Benefit Rate In Frontline AML As Emerging Data Demonstrate Additive Benefit To Standard Of Care Treatment	EQ
26/03	Aptevo Provides State of the Business Report and 2025 Financial Results	AQ
23/03	Aptevo Therapeutics : 23 March 2026 Investor Presentation	PU
19/03	Aptevo to Participate in March 2026 Conferences	AQ
30/11/-1	Mipletamig Delivers Compelling 86% Clinical Benefit Rate and No CRS as Evaluable AML Patient Data increases by Nearly 50%	AQ
30/11/-1	Aptevo Announces Executive Leadership Transitions to Support Next Phase of Growth	AQ
30/11/-1	Aptevo Therapeutics Secures $60 Million Equity Line of Credit to Support Multispecific Portfolio Advancement, Increase Strategic Optionality	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Articles Zonebourse Analyses Zonebourse

Filtres

Dès maintenant, trouvez facilement les meilleurs investissements de demain !